Mirati Therapeutics Inc MRTX:NASDAQ

Last Price$132.04NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/01/21

Today's Change-4.73(3.46%)
Bid (Size)$128.82 (1)
Ask (Size)$136.94 (1)
Day Low / High$131.83 - 139.22
Volume483.2 K
 

View Biotechnology IndustryPeer Comparison as of 12/01/2021

 

Mirati Therapeutics Inc ( NASDAQ )

Price: $132.04
Change: -4.73 (3.46%)
Volume: 483.2 K
4:00PM ET 12/01/2021
 
 

Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $67.00
Change: -3.05 (4.35%)
Volume: 700.0 K
4:00PM ET 12/01/2021
 
 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $80.79
Change: -2.46 (2.95%)
Volume: 983.4 K
4:00PM ET 12/01/2021
 
 

Sarepta Therapeutics Inc ( NASDAQ )

Price: $82.19
Change: +1.38 (1.71%)
Volume: 852.6 K
4:00PM ET 12/01/2021
 
 

Intellia Therapeutics Inc ( NASDAQ )

Price: $106.92
Change: -8.09 (7.03%)
Volume: 17.00
4:00PM ET 12/01/2021
 

Read more news Recent News

BMO Capital Starts Mirati Therapeutics at Outperform With $187 Price Target
5:59AM ET 11/19/2021 MT Newswires

Mirati Therapeutics (MRTX) has an average rating of outperform and price targets ranging from $171 to $287, according to analysts polled by Capital IQ. (MT...

Mirati Therapeutics Submits Investigational New-Drug Application to FDA for MRTX1719 to Treat MTAP-Deleted Cancers
9:34AM ET 11/17/2021 MT Newswires

Mirati Therapeutics (MRTX) said Wednesday it has submitted an investigational new-drug application to the US Food and Drug Administration to evaluate...

Mirati Therapeutics Q3 Loss Narrows as Revenue Surges
4:17PM ET 11/08/2021 MT Newswires

Mirati Therapeutics (MRTX) reported after markets closed Monday a Q3 net loss of $1.55 per diluted share, narrower than a per-share loss of $1.96 a year...

-- Earnings Flash (MRTX) MIRATI THERAPEUTICS Posts Q3 Revenue $71.8M
4:03PM ET 11/08/2021 MT Newswires

...

Company Profile

Business DescriptionMirati Therapeutics, Inc. operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm's products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA. View company web site for more details
Address3545 Cray Court
San Diego, California 92121
Phone+1.858.332.3410
Number of Employees63
Recent SEC Filing11/12/20218-K
Chief Executive Officer & DirectorDavid D. Meek
President, Director & Head-Research & DevelopmentCharles M. Baum
Chief Financial & Accounting OfficerVickie S. Reed
Chief Scientific Officer & Executive VPJames G. Christensen

Company Highlights

Price Open$136.84
Previous Close$132.04
52 Week Range$131.47 - 249.42
Market Capitalization$6.8 B
Shares Outstanding51.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$9.54
Beta vs. S&P 500N/A
Revenue$12.9 M
Net Profit Margin-657.48%
Return on Equity-39.99%

Analyst Ratings as of 11/17/2021

Buy
11
Overweight
0
Hold
4
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset